Literature DB >> 30973065

MicroRNA-543 promotes cell invasion and impedes apoptosis in pituitary adenoma via activating the Wnt/β-catenin pathway by negative regulation of Smad7.

Da-Wei Shen1, Yun-Long Li1, Yu-Jie Hou2, Zhi-Dan Xu3, Yong-Zhe Li4, Jian-Yong Chang5.   

Abstract

Pituitary adenomas (PA) are commonly occurring benign neoplasms. Identification of molecular pathway resulting in pituitary tumorigenesis remains challenges in endocrine oncology. The present study was conducted with aim of investigating the role of microRNA-543 (miR-543) in PA development. Up-regulated miR-543 and downregulated Smad7 were observed in PA tissues. Afterwards, the specific mechanism of miR-543 and Smad7 in PA were determined with the use of ectopic expression, depletion and reporter assay experiments. Smad7 was confirmed as a target gene of miR-543. HP75 cells treated with overexpressed miR-543 exhibited increased cell proliferation, migration and invasion, while decreased cell apoptosis as well as expression of Cleaved caspase-3 and Cleaved caspase-8 were observed. Suppression of miR-543 contributed to an opposite trend to the above findings. Based on the findings, the inhibition of miR-543 was found to play a tumor suppressive role in PA through the down-regulation of Wnt/β-catenin pathway by negatively regulating Smad7.

Entities:  

Keywords:  MicroRNA-543; Wnt/β-catenin pathway; apoptosis; invasion; mothers against decapentaplegic homolog 7; pituitary adenoma

Mesh:

Substances:

Year:  2019        PMID: 30973065     DOI: 10.1080/09168451.2019.1591260

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  9 in total

1.  miR-543 promoted the cell proliferation and invasion of nasopharyngeal carcinoma by targeting the JAM-A.

Authors:  Xue Jiang; Baoqiang Dai; Lichun Feng
Journal:  Hum Cell       Date:  2019-08-19       Impact factor: 4.174

2.  Clinical significance of miR-181a in patients with neonatal sepsis and its regulatory role in the lipopolysaccharide-induced inflammatory response.

Authors:  Guozhi Liu; Wei Liu; Jie Guo
Journal:  Exp Ther Med       Date:  2020-01-02       Impact factor: 2.447

Review 3.  Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome.

Authors:  Simone Donati; Simone Ciuffi; Francesca Marini; Gaia Palmini; Francesca Miglietta; Cinzia Aurilia; Maria Luisa Brandi
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

Review 4.  The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma.

Authors:  Soudeh Ghafouri-Fard; Atefe Abak; Bashdar Mahmud Hussen; Mohammad Taheri; Guive Sharifi
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

5.  Reactivation of Multiple Fetal miRNAs in Lung Adenocarcinoma.

Authors:  David E Cohn; Mateus C Barros-Filho; Brenda C Minatel; Michelle E Pewarchuk; Erin A Marshall; Emily A Vucic; Adam P Sage; Nikita Telkar; Greg L Stewart; Igor Jurisica; Patricia P Reis; Wendy P Robinson; Wan L Lam
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

6.  Higher miR-543 levels correlate with lower STK31 expression and longer pancreatic cancer survival.

Authors:  Weizhong Yuan; Hao Gao; Guangfu Wang; Yi Miao; Kuirong Jiang; Kai Zhang; Junli Wu
Journal:  Cancer Med       Date:  2020-10-30       Impact factor: 4.452

7.  Silencing circular RNAPTPN12 promoted the growth of keloid fibroblasts by activating Wnt signaling pathway via targeting microRNA-21-5p.

Authors:  Fei Liu; Tao Li; Xiaoan Zhan
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

8.  MiR-543 promotes tumorigenesis and angiogenesis in non-small cell lung cancer via modulating metastasis associated protein 1.

Authors:  Dawei Wang; Li Cai; Xudong Tian; Wenjun Li
Journal:  Mol Med       Date:  2020-05-14       Impact factor: 6.376

Review 9.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.

Authors:  Vinaya Srirangam Nadhamuni; Márta Korbonits
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.